• IceCure received a 180-day Nasdaq extension to regain compliance with minimum bid requirement, setting a new deadline of Nov. 9, 2026.
• Ordinary shares continue to trade on Nasdaq Capital Market under symbol ICCM, with no immediate impact on listing or trading.
• Compliance can be regained if closing bid price is at least $1 for at least 10 consecutive business days before deadline; reverse share split flagged as potential remedy if needed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN59166) on May 13, 2026, and is solely responsible for the information contained therein.